ethinylestradiol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| estrogens | 1082 | 57-63-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mcg | O |
| 1.50 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 3 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 4.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 7 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.70 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 25, 1943 | FDA | SCHERING | |
| July 23, 2010 | PMDA | Bayer Yakuhin |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Muscle spasticity | 67.21 | 26.47 | 28 | 2833 | 17156 | 50585107 |
| Ear pain | 59.70 | 26.47 | 30 | 2831 | 28253 | 50574010 |
| Night sweats | 57.63 | 26.47 | 31 | 2830 | 33543 | 50568720 |
| Body temperature increased | 53.96 | 26.47 | 29 | 2832 | 31312 | 50570951 |
| Respiratory disorder | 51.31 | 26.47 | 28 | 2833 | 31159 | 50571104 |
| Lower respiratory tract infection | 49.91 | 26.47 | 42 | 2819 | 95159 | 50507104 |
| Unresponsive to stimuli | 46.29 | 26.47 | 26 | 2835 | 30583 | 50571680 |
| Cerebral venous sinus thrombosis | 41.47 | 26.47 | 11 | 2850 | 1657 | 50600606 |
| Pruritus | 41.03 | 26.47 | 64 | 2797 | 283504 | 50318759 |
| Sinusitis | 37.33 | 26.47 | 47 | 2814 | 170511 | 50431752 |
| Ovarian atrophy | 36.12 | 26.47 | 6 | 2855 | 89 | 50602174 |
| Pulmonary embolism | 30.54 | 26.47 | 33 | 2828 | 101671 | 50500592 |
| Drug level decreased | 30.16 | 26.47 | 12 | 2849 | 6521 | 50595742 |
| Peripheral swelling | 29.05 | 26.47 | 46 | 2815 | 205890 | 50396373 |
| Urticaria | 27.20 | 26.47 | 35 | 2826 | 129526 | 50472737 |
| Joint swelling | 26.94 | 26.47 | 49 | 2812 | 245237 | 50357026 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Muscle spasticity | 74.71 | 32.62 | 27 | 2460 | 16642 | 64479603 |
| Ear pain | 70.69 | 32.62 | 29 | 2458 | 25107 | 64471138 |
| Night sweats | 66.82 | 32.62 | 31 | 2456 | 36015 | 64460230 |
| Body temperature increased | 57.16 | 32.62 | 28 | 2459 | 36638 | 64459607 |
| Respiratory disorder | 54.58 | 32.62 | 27 | 2460 | 36084 | 64460161 |
| Lower respiratory tract infection | 52.59 | 32.62 | 37 | 2450 | 94577 | 64401668 |
| Cerebral venous sinus thrombosis | 49.57 | 32.62 | 12 | 2475 | 1843 | 64494402 |
| Sinusitis | 46.31 | 32.62 | 41 | 2446 | 145887 | 64350358 |
| Pruritus | 42.49 | 32.62 | 56 | 2431 | 312344 | 64183901 |
| Ovarian atrophy | 38.61 | 32.62 | 6 | 2481 | 86 | 64496159 |
| Unresponsive to stimuli | 38.37 | 32.62 | 24 | 2463 | 50369 | 64445876 |
| Joint swelling | 36.26 | 32.62 | 43 | 2444 | 215339 | 64280906 |
| Ovarian failure | 33.69 | 32.62 | 7 | 2480 | 538 | 64495707 |
| Contraindicated product administered | 33.58 | 32.62 | 30 | 2457 | 107799 | 64388446 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03AA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA03 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA06 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA07 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA09 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA10 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA11 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA12 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA13 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA15 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AA16 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03AB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB03 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB06 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB07 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03AB09 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
| ATC | G03CA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Natural and semisynthetic estrogens, plain |
| ATC | L02AA03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Estrogens |
| FDA MoA | N0000000100 | Estrogen Receptor Agonists |
| CHEBI has role | CHEBI:76988 | xenoestrogens |
| MeSH PA | D003270 | Contraceptive Agents |
| MeSH PA | D003271 | Contraceptive Agents, Female |
| MeSH PA | D000080066 | Contraceptive Agents, Hormonal |
| MeSH PA | D003278 | Contraceptives, Oral, Hormonal |
| MeSH PA | D004967 | Estrogens |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D012102 | Reproductive Control Agents |
| FDA EPC | N0000175825 | Estrogen |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Premenstrual dysphoric disorder | indication | 596004 | |
| Contraception | indication | 13197004 | |
| Atrophic vaginitis | indication | 52441000 | |
| Acne vulgaris | indication | 88616000 | |
| Postmenopausal osteoporosis | indication | 102447009 | |
| Menopausal flushing | indication | 198436008 | |
| Atrophic vulva | indication | 248861000 | DOID:14275 |
| Dysmenorrhea | indication | 266599000 | |
| Amenorrhea | off-label use | 14302001 | DOID:13938 |
| Female hypogonadism syndrome | off-label use | 16041008 | |
| Polycystic ovaries | off-label use | 69878008 | |
| Postcoital contraception | off-label use | 268463003 | |
| Abnormal uterine bleeding unrelated to menstrual cycle | off-label use | 312984006 | |
| Menorrhagia | off-label use | 386692008 | |
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
| Hypocalcemia | contraindication | 5291005 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Jaundice | contraindication | 18165001 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Diplopia | contraindication | 24982008 | |
| Retinal hemorrhage | contraindication | 28998008 | |
| Depressive disorder | contraindication | 35489007 | |
| Chloasma | contraindication | 36209000 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Body fluid retention | contraindication | 43498006 | |
| Thrombosis of retinal vein | contraindication | 46085004 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Chronic heart failure | contraindication | 48447003 | |
| Dementia | contraindication | 52448006 | |
| Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Benign mammary dysplasia | contraindication | 57993004 | |
| Acute nephropathy | contraindication | 58574008 | |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Intermenstrual bleeding - irregular | contraindication | 64996003 | |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Breast lump | contraindication | 89164003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
| Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Deep venous thrombosis | contraindication | 128053003 | |
| Seizure disorder | contraindication | 128613002 | |
| Endometriosis | contraindication | 129103003 | |
| Bed-ridden | contraindication | 160685001 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Mammography abnormal | contraindication | 168750009 | |
| Angina pectoris | contraindication | 194828000 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Thrombophilia | contraindication | 234467004 | DOID:2452 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cholestasis of pregnancy | contraindication | 235888006 | |
| Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Chorea | contraindication | 271700006 | |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Functional visual loss | contraindication | 313165001 | |
| Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
| Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
| Cardiovascular event risk | contraindication | 395112001 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Estrogen receptor positive tumor | contraindication | 416053008 | |
| Porphyria | contraindication | 418470004 | |
| Optic disc edema | contraindication | 423341008 | DOID:146 |
| Family history of malignant neoplasm of breast | contraindication | 429740004 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication | ||
| Major Surgery with Prolonged Post-Operative Immobilization | contraindication | ||
| Diabetes with Vascular Disease Complication | contraindication | ||
| Benign Hepatic Cell Adenoma | contraindication | ||
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.13 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG | BEYAZ | BAYER HLTHCARE | N022532 | Sept. 24, 2010 | RX | TABLET | ORAL | 7163931 | March 3, 2022 | PREVENTION OF PREGNANCY |
| 3MG,N/A;0.03MG,N/A;0.451MG,0.451MG | SAFYRAL | BAYER HLTHCARE | N022574 | Dec. 16, 2010 | RX | TABLET | ORAL | 7163931 | March 3, 2022 | PREVENTION OF PREGNANCY |
| 0.03MG,0.01MG;0.15MG,N/A | SEASONIQUE | TEVA BRANDED PHARM | N021840 | May 25, 2006 | RX | TABLET | ORAL | 7615545 | June 15, 2023 | PREVENTION OF PREGNANCY |
| 0.02MG,0.1MG;0.01MG,N/A | LOSEASONIQUE | TEVA BRANDED PHARM | N022262 | Oct. 24, 2008 | RX | TABLET | ORAL | 7615545 | June 15, 2023 | PREVENTION OF PREGNANCY |
| 0.03MG,0.01MG;0.15MG,N/A | SEASONIQUE | TEVA BRANDED PHARM | N021840 | May 25, 2006 | RX | TABLET | ORAL | 7320969 | Jan. 30, 2024 | PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION |
| 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A | QUARTETTE | TEVA BRANDED PHARM | N204061 | March 28, 2013 | RX | TABLET | ORAL | 8450299 | Oct. 7, 2025 | PREVENTION OF PREGNANCY |
| 0.02MG;0.1MG | BALCOLTRA | AVION PHARMS | N208612 | Jan. 9, 2018 | RX | TABLET | ORAL | 7838042 | June 1, 2027 | ADMINISTRATION OF FERROUS BISGLYCINATE TABLETS |
| 0.03MG,0.01MG;0.15MG,N/A | SEASONIQUE | TEVA BRANDED PHARM | N021840 | May 25, 2006 | RX | TABLET | ORAL | 7855190 | Dec. 5, 2028 | PREVENTION OF PREGNANCY |
| 0.02MG,0.1MG;0.01MG,N/A | LOSEASONIQUE | TEVA BRANDED PHARM | N022262 | Oct. 24, 2008 | RX | TABLET | ORAL | 7855190 | Dec. 5, 2028 | PREVENTION OF PREGNANCY |
| 0.01MG,0.01MG;1MG,N/A | LO LOESTRIN FE | APIL | N022501 | Oct. 21, 2010 | RX | TABLET | ORAL | 7704984 | Feb. 2, 2029 | LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION |
| 0.01MG,0.01MG,N/A;1MG,N/A,N/A | LO MINASTRIN FE | APIL | N204654 | July 24, 2013 | DISCN | TABLET, CHEWABLE, TABLET | ORAL | 7704984 | Feb. 2, 2029 | PREVENTION OF PREGNANCY |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | 10632066 | Feb. 1, 2039 | METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | 10632066 | Feb. 1, 2039 | METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | 10765628 | Feb. 1, 2039 | METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | 10765628 | Feb. 1, 2039 | METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | 10780047 | Feb. 1, 2039 | METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | 10780047 | Feb. 1, 2039 | METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.03MG/24HR;0.12MG/24HR | TWIRLA | AGILE | N204017 | Feb. 14, 2020 | RX | SYSTEM | TRANSDERMAL | Feb. 14, 2023 | NEW PRODUCT |
| 0.02MG;0.1MG | TYBLUME | EXELTIS USA INC | N209405 | March 30, 2020 | RX | TABLET | ORAL | March 30, 2023 | NEW DOSAGE FORM |
| 0.013MG/24HR;0.15MG/24HR | ANNOVERA | THERAPEUTICSMD INC | N209627 | Aug. 10, 2018 | RX | RING | VAGINAL | Aug. 10, 2023 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | AGONIST | Kd | 9.83 | WOMBAT-PK | CHEMBL | |||
| Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | IC50 | 5.52 | CHEMBL | |||||
| Mu-type opioid receptor | GPCR | Ki | 4.96 | DRUG MATRIX | |||||
| Adenosine receptor A2a | GPCR | Ki | 4.93 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 7.54 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.02 | DRUG MATRIX | |||||
| Aldehyde oxidase | Enzyme | IC50 | 6.24 | WOMBAT-PK | |||||
| Glucocorticoid receptor | Nuclear hormone receptor | Ki | 6.11 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 6.35 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 4.73 | DRUG MATRIX | |||||
| Kappa-type opioid receptor | GPCR | Ki | 4.99 | DRUG MATRIX | |||||
| Androgen receptor | Nuclear hormone receptor | IC50 | 7.30 | WOMBAT-PK | |||||
| Estrogen receptor beta | Nuclear hormone receptor | IC50 | 8.09 | CHEMBL | |||||
| Sex hormone-binding globulin | Secreted | Kd | 6.81 | CHEMBL | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 5.66 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 4.68 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.69 | CHEMBL | |||||
| Androgen receptor | Transcription factor | IC50 | 5.09 | CHEMBL | |||||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.25 | DRUG MATRIX | |||||
| Progesterone receptor | Transcription factor | Ki | 6.86 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 4 | GPCR | Ki | 5.88 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 423D2T571U | UNII |
| 4018022 | VUID |
| N0000146366 | NUI |
| D00554 | KEGG_DRUG |
| 4018022 | VANDF |
| C0015011 | UMLSCUI |
| CHEBI:4903 | CHEBI |
| 3WF | PDB_CHEM_ID |
| CHEMBL691 | ChEMBL_ID |
| 5991 | PUBCHEM_CID |
| DB00977 | DRUGBANK_ID |
| D004997 | MESH_DESCRIPTOR_UI |
| 437 | INN_ID |
| 7071 | IUPHAR_LIGAND_ID |
| 4124 | RXNORM |
| 4698 | MMSL |
| 72166 | MMSL |
| d00229 | MMSL |
| 001286 | NDDF |
| 126097006 | SNOMEDCT_US |
| 15432003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NuvaRing | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0052-0273 | INSERT, EXTENDED RELEASE | 0.02 mg | VAGINAL | NDA | 28 sections |
| Jinteli | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-3122 | TABLET | 5 ug | ORAL | ANDA | 29 sections |
| Etonogestrel and Ethinyl Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7679 | INSERT, EXTENDED RELEASE | 0.02 mg | VAGINAL | ANDA | 29 sections |
| XULANE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-3340 | PATCH | 35 ug | TRANSDERMAL | ANDA | 28 sections |
| XULANE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-3340 | PATCH | 35 ug | TRANSDERMAL | ANDA | 28 sections |
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7274 | TABLET | 0.03 mg | ORAL | ANDA | 15 sections |
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7274 | TABLET | 0.03 mg | ORAL | ANDA | 15 sections |
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7280 | TABLET | 0.02 mg | ORAL | ANDA | 15 sections |
| femhrt | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0430-0145 | TABLET | 2.50 ug | ORAL | NDA | 33 sections |
| Nortrel21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9009 | TABLET | 0.04 mg | ORAL | ANDA | 21 sections |
| Junel21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9025 | TABLET | 20 ug | ORAL | ANDA | 15 sections |
| Junel21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9027 | TABLET | 30 ug | ORAL | ANDA | 15 sections |
| Levonorgestrel and Ethinyl Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0295 | TABLET | 20 ug | ORAL | ANDA | 24 sections |
| NUVARING | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1008 | INSERT, EXTENDED RELEASE | 0.02 mg | VAGINAL | NDA | 27 sections |
| XULANE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1683 | PATCH | 35 ug | TRANSDERMAL | ANDA | 29 sections |
| XULANE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1683 | PATCH | 35 ug | TRANSDERMAL | ANDA | 29 sections |
| NUVARING | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-5611 | INSERT, EXTENDED RELEASE | 0.02 mg | VAGINAL | NDA | 27 sections |
| Etonogestrel/Ethinyl Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-5959 | INSERT, EXTENDED RELEASE | 0.02 mg | VAGINAL | NDA AUTHORIZED GENERIC | 29 sections |
| ANNOVERA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50261-313 | RING | 17.40 mg | VAGINAL | NDA | 32 sections |
| ANNOVERA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50261-313 | RING | 17.40 mg | VAGINAL | NDA | 32 sections |
| Dolishale | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50742-659 | TABLET | 20 ug | ORAL | ANDA | 15 sections |
| Loestrin21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51285-127 | TABLET | 30 ug | ORAL | ANDA | 15 sections |
| Loestrin21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51285-131 | TABLET | 20 ug | ORAL | ANDA | 15 sections |
| MICROGESTIN 1/20 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51862-007 | TABLET | 20 ug | ORAL | NDA authorized generic | 21 sections |
| MICROGESTIN 1/20 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51862-007 | TABLET | 20 ug | ORAL | NDA authorized generic | 21 sections |
| MICROGESTIN 1.5/30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51862-279 | TABLET | 30 ug | ORAL | NDA authorized generic | 21 sections |
| MICROGESTIN 1.5/30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51862-279 | TABLET | 30 ug | ORAL | NDA authorized generic | 21 sections |
| Amethyst | HUMAN PRESCRIPTION DRUG LABEL | 2 | 52544-295 | TABLET | 20 ug | ORAL | ANDA | 24 sections |
| Amethyst | HUMAN PRESCRIPTION DRUG LABEL | 2 | 52544-295 | TABLET | 20 ug | ORAL | ANDA | 24 sections |
| MICROGESTIN 1/20 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53002-1549 | TABLET | 20 ug | ORAL | NDA AUTHORIZED GENERIC | 21 sections |